Alvotech (ALVO) Stock News

Alvotech (NASDAQ: ALVO) reported strong Q1 2025 financial results, with total revenues reaching $132.8 million, a 260% increase year-over-year. Product revenues surged 786% to $109.9 million, while Adjusted EBITDA improved to $20.5 million from negative $38.4 million in 2023.

The company increased its full-year guidance to $600-$700 million in revenue and $200-280 million in adjusted EBITDA, following the acquisition of Xbrane's R&D operations and rights to a proposed Cimzia biosimilar. Notable achievements include the U.S. launch of SELARSDI™ (ustekinumab-aekn), a Stelara® biosimilar, and BLA filing acceptances for biosimilars to Simponi®, Eylea®, and Prolia/Xgeva.

The company reported a net profit of $109.7 million ($0.39 per share) and expects to be free cash-flow positive in 2025.

Alvotech (ALVO) has announced the granting of stock options to four independent board directors and the vesting of previously awarded Restricted Share Units (RSUs). Each director received options to purchase 24,784 Alvotech shares at an exercise price of $9.28 per share.

The stock options will vest over a three-year period, with one-third vesting each year starting from the grant date of June 25, 2025. Directors must remain board members at the time of vesting to exercise their options. The exercise price was determined by the opening price of Alvotech's ordinary shares on Nasdaq US on the grant date.

Alvotech (NASDAQ: ALVO) has entered into a supply and commercialization agreement with Advanz Pharma for AVT10, a biosimilar candidate to Cimzia® (certolizumab pegol). The agreement focuses on the European market and expands the existing strategic partnership between the two companies.

Notably, Alvotech's biosimilar candidate is currently the only one under development globally referencing Cimzia®, a TNF-alpha inhibitor used for treating chronic rheumatic diseases. The reference product Cimzia® generated worldwide sales of US$2.3 billion in 2024.

This agreement adds to the existing partnership between Alvotech and Advanz Pharma, which already covers biosimilar candidates for more than ten reference biologics. The companies anticipate launching their first biosimilars in Europe in Q4 2025.

Alvotech (NASDAQ: ALVO) announced that its lenders have agreed to reduce interest rates on its senior secured term loan facility, resulting in estimated savings of $8.2 million in interest payments over the first 12 months. The agreement reflects the company's improved operational performance and stronger financial position.

The facility, maturing in July 2029, will consolidate its two tranches into a single tranche with an interest rate of SOFR plus 6.0% per annum, down from previous rates of SOFR plus 6.5% and 10.5%. The total facility balance stands at $1,081 million, with a company cash balance of $152 million as of June 25, 2025.

Alvotech (ALVO) held its 2025 Annual and Extraordinary General Meeting on June 25, 2025 in Luxembourg. The company announced that all proposed resolutions on the meeting agenda were successfully approved by shareholders. The official notarized meeting minutes and detailed voting results will be made available on the company's investor relations website.

Alvotech (NASDAQ: ALVO), in partnership with Kashiv Biosciences and Advanz Pharma, announced positive topline results from their confirmatory efficacy study for AVT23, a proposed biosimilar to Xolair® (omalizumab). The study met its primary endpoint, demonstrating therapeutic equivalence and comparable safety to Xolair® in patients with Chronic Spontaneous Urticaria (CSU).

The double-blind study enrolled 600 patients, with 400 receiving the confirmatory dose of 300mg. The primary efficacy measure focused on changes in weekly Itch Severity Score at Week 12. The UK MHRA has already validated the marketing authorization application, with an EMA filing expected by year-end.

Alvotech (NASDAQ: ALVO) and Advanz Pharma announced that the EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended approval for AVT06, their proposed biosimilar to Eylea (aflibercept 2 mg). The biosimilar is intended to treat various eye disorders including wet age-related macular degeneration, visual impairment due to macular oedema, diabetic macular oedema, and myopic choroidal neovascularisation. Alvotech will handle development and commercial supply, while Advanz Pharma will manage registration and exclusive commercialization in most European countries. Notably, Eylea's global sales reached approximately $9 billion in 2024, with one-third coming from Europe. A confirmatory clinical study completed in January 2024 demonstrated therapeutic equivalence between AVT06 and Eylea. Additionally, Alvotech is developing AVT29, a proposed biosimilar to the higher-dose Eylea HD (aflibercept 8 mg).

Alvotech (NASDAQ: ALVO) has successfully completed a private placement of shares and Swedish Depositary Receipts (SDRs) announced on June 4, 2025. The placement attracted approximately 40 institutional investors, with 60% of demand coming from Sweden, Norway, and UK investors, and 30% from US-based funds. Notably, over 80% of the allocated shares and SDRs were purchased by new investors. The placement involved the transfer of 7.5 million treasury shares from Alvotech's subsidiary Alvotech Manco ehf. According to CEO Róbert Wessman, this placement will diversify and strengthen Alvotech's shareholder base while increasing the free float of SDRs on Nasdaq Stockholm, where approximately 8.5 million SDRs are currently trading.

Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, announced its participation in the Goldman Sachs 46th Global Healthcare Conference in Miami from June 9-11, 2025. The company's management team will conduct one-on-one meetings during the event. Dr. Balaji Prasad, Chief Strategy Officer, will participate in a fireside chat on June 11 at 8:00 am EDT. The session will be webcast live and accessible to the public through Alvotech's investor relations website, with a replay available for 90 days following the event.